# Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

> **NCT01088048** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 241 (actual)

## Conditions studied

- Indolent Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Ofatumumab
- **DRUG:** Fludarabine
- **DRUG:** Everolimus
- **DRUG:** Bortezomib
- **DRUG:** Chlorambucil
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01088048
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-25
- **Primary completion:** 2015-04-28
- **Final completion:** 2015-04-28
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088048, "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01088048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*